

LITERATURA

1. Abalovich M, Vázquez A, Alcaraz G, Kitaigrotsky A, Szuman G, Calabrese C et al. Adequate levothyroxine doses for the treatment of hypothyroidism newly discovered during pregnancy. *Thyroid*. 2013;23(11):1479–83.
2. Adroge HJ, Madias NE. Hyponatremia. *New Engl J Med*. 2000;342:1581–9.
3. Amar L, Plouin PF, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. *Orphanet J Rare Dis*. 2010;5:9.
4. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, et al. United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). Health Status of Adults with Congenital Adrenal Hyperplasia: A Cohort Study of 203 Patients. *J Clin Endocrinol Metab*. 2010;95(11):5110–21.
5. Asa SL, Casar-Borota O, Chanson P, Delgrange E, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. *Endocrine Related Cancer*. 2017;24:C5–8.
6. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. *Eur J Endocrinol*. 2008;158:273–85.
7. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. *J Clin Endocrinol Metab*. 2014;99:3561–69.
8. Braunstein GD. Hypothalamic Syndromes. In: Jameson JL, DeGroot LJ, editors. *Endocrinology*. 6th ed. W. B. Saunders; 2010. p. 230–342.
9. Boccalatte LA et al. *JAMA Otolaryngol. Head Neck Surg*. 2019;743–750.
10. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? *Eur J Endocrinol*. 2009;161:513–27.
11. Cibas ES, Ali SZ. The Bethesda 2017 System for Reporting Thyroid Cytopathology. *Thyroid*. 2017;27:1341–1346.
12. Cooper TG et al. World Health Organization reference values for human semen characteristics. *Human Reproduction Update*. 2010;16(3):231–45.
13. Čáp J. Uzel štítné žlázy. *Klin Farmakol Farm*. 2011;25(1):28–32.

14. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: A cross-sectional study in the province of Liège, Belgium. *J Clin Endocrinol Metab.* 2006;91:4769–75.
15. Dauber A, Kellogg M, Majzoub JA. Monitoring of Therapy in Congenital Adrenal Hyperplasia. *Clin Chem.* 2010;56(8):1245–51.
16. Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and Pathological Aspects of Silent Pituitary Adenomas. *J Clin Endocrinol Metab.* 2019;104(7):2473–89.
17. Fassnacht M, et al. ESE Clinical Practice Guidelines on the management of adrenocortical carcinoma. *Eur J Endocrinol* 2018;179(4):G1–46.
18. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. *Eur J Endocrinol.* 2016;175(2):G1–34.
19. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community based, cross-sectional study in Banbury (Oxfordshire). *Clin Endocrinol (Oxf).* 2010;72:377–82.
20. Ferriman DM, Gallwey JD. Clinical assessment of body hair growth in women. *J Clin Endocrinol.* 1961;21:1440–7.
21. Fisseler-Eckhoff A, Demes M. Neuroendocrine Tumors of the Lung. *Cancers.* 2012;4:777–98.
22. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2008;93:3266–81.
23. Haddad RI, Nasr C, Bischoff L, et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018, JNCCN. 2018;16:1429–40.
24. Hána V. Hypopituitarismus a diabetes insipidus centralis. Praha: Maxdorf; 2011.
25. Hána V, Kosák M, Hána V jr. Hypogonadismus u mužů a jeho léčba. *Čas Lék Čes.* 2017;156:258–65.
26. Harris PE, Bouloux PMG. Endocrinology in clinical practice. CRC Press; 2014.
27. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid.* 2016;26(1):1–133.
28. Jameson JL, DeGroot LJ. Endocrinology, 6th ed. W.B. Saunders Company, 2010.
29. Kaltsas G, et al. Current Status and Controversies in adrenal incidentalomas. *Trends Endocrin Metabolism,* 2012;23(12):602–9.
30. Kasper DL, Braunwald E, Fauci AS, et al., editors. Harrison's Principles of Internal Medicine. 16th ed. McGraw Hill; 2005.
31. Katznelson L et al. Global clinical response in Cushing's syndrome patients treated with mifepristone. *Clin Endo.* 2014;80:562–9.

32. Katznelson, L, Atkinson, JL, Cook, DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. *Endocrine Pract.* 2011;17(Suppl 4):1–44.
33. Khan AA, Bilezikian JP, Potts JT Jr. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. On behalf of the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. *J Clin Endocrinol Metab.* 2009;94:333–4.
34. Kršek M, Jiskra J, Krátký J. Vyšetření krku UZ. In: Marek J, Hána V, et al., editors. *Endokrinologie*. Praha; Galén: 2017.
35. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. *Williams Textbook of Endocrinology*. 10th ed. Philadelphia: W. B. Saunders; 2003.
36. Lebl J, Janda J, et al. *Klinická pediatrie*. Praha: Galén; 2012.
37. Loh JA, Verbalis JG. Disorders of Water and Salt Metabolism Associated with Pituitary Disease. *Endocrinol Metab Clin N Am.* 2008;37:213–34.
38. Marek J, et al. *Farmakoterapie vnitřních nemocí*. 4th ed. Praha: Grada; 2010.
39. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. *J Clin Endocrinol Metab.* 2002;87(5):1941–6.
40. Phyllis W. Speiser, Ricardo Azziz, Laurence S. Baskin, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2010;95(9):4133–60.
41. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. *Modern Pathology.* 2018;31:1770–86.
42. Schmidbauer B, Menhart K, Hellwig D, et al. Differentiated Thyroid Cancer-Treatment: State of the Art. *Int J Mol Sci.* 2017;18(6).pii:E1292.
43. Smith DM, McKenna K, Thompson CJ. Hyponatremia. *Clin Endocrinol (Oxf.)*. 2000;52:668–78.
44. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Europ J Endocrinol.* 2014;170:G1–47.
45. Tajar et al.: Characteristics of androgen deficiency in LOH: results from the European Male Aging Study (EMAS). *JCEM.* 2012;97:1508–1516.
46. Terzolo M, Stigliano A, Chiodini I, et al. AME Position Statement on adrenal incidentaloma. *Eur J Endocrinol.* 2011;164:851–70.
47. Wang et al.: ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of LOH in males. *Aging Male.* 2009;12:5–12.
48. Whitaker MJ, Debono M, Huatan H, Merke DP, Arlt W, Ross RJ. An oral multiparticulate, modified-release, hydrocortisone replacement

- therapy that provides physiological cortisol exposure. *Clin Endocrinol (Oxf)*. 2014;80(4):554–61.
49. Widimský J. Mineralokortikoidně podmíněné hypertenze. In: Marek J, Hána V, et al., editors. *Endokrinologie*. Praha: Galén; 2017;p. 349–54.
50. Wilson JD, Foster DW. *Williams Textbook of Endocrinology*. 10th ed. W.B. Saunders; 2003.
51. Young WF. Primary aldosteronism: renaissance of a syndrome. *Clin Endocrinol*. 2007;66:607–18.
52. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. *J Clin Endocrinol Metab*. 2011; 96(7):2004–15.